Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/21/14 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
38 | |
| 08/19/14 | 8-K | Current report filing |
|
4 | |
| 08/15/14 | 8-K | Current report filing |
|
11 | |
| 08/14/14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
44 |
| 07/03/14 | 8-K | Current report filing |
|
125 | |
| 05/30/14 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 05/15/14 | 8-K | Current report filing |
|
11 | |
| 05/15/14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
48 |
| 04/17/14 | EFFECT | Notice of Effectiveness |
|
1 | |
| 04/08/14 | 8-K | Current report filing |
|
5 |
